Thalidomide resistance is based on the capacity of the glutathione- dependent antioxidant defense

Molecular Pharmaceutics

Volumn 5, Issue 6, 2008, Pages 1138-1144

  Knobloch, Jürgen ^a,b   Reimann, Kerstin ^a   Klotz, Lars Oliver ^a   Rüther, Ulrich ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Antioxidant defense; Apoptosis; Drug resistance; Glutathione; Mouse embryonic cells; Superoxide; Teratogenic; Thalidomide

Indexed keywords

ACETYLCYSTEINE; GLUTATHIONE; SUPEROXIDE; THALIDOMIDE;

ANIMAL CELL; ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; CONTROLLED STUDY; CULTURE MEDIUM; EMBRYO; EMBRYO DEVELOPMENT; EXPERIMENTAL MODEL; FIBROBLAST; HUMAN; HUMAN CELL; MOLECULAR MECHANICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPLETION; STAINING; TERATOGENICITY;

ACETYLCYSTEINE; ANIMALS; ANTIOXIDANTS; APOPTOSIS; CELL SURVIVAL; CELLS, CULTURED; CHICKENS; CULTURE MEDIA, CONDITIONED; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE; EMBRYO, MAMMALIAN; EMBRYO, NONMAMMALIAN; FIBROBLASTS; FREE RADICAL SCAVENGERS; GLUTATHIONE; HUMANS; MICE; SUPEROXIDES; TERATOGENS; THALIDOMIDE; TIME FACTORS;

EID: 61349192318     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp8001232     Document Type: Article

References (18)

1. Lenz, W. A short history of thalidomide embryopathy. Teratology 1988, 38, 203-215.
2. Teo, S. K.; Stirling, D. I.; Zeldis, J. B. Thalidomide as a novel therapeutic agent: new uses for an old product. Drug Discovery Today 2005, 10, 107-114.
3. Newman, L. M.; Johnson, E. M.; Staples, R. E. Assessment of the effectiveness of animal developmental toxicity testing for human safety. Reprod. Toxicol 1993, 7, 359-390.
4. Knobloch, J.; Shaughnessy, J. D., Jr; Riither, U. Thalidomide induces limb deformities by perturbing the Bmp/Dkkl/Wnt signaling pathway. FASEB J. 2007, 21, 1410-1421.
5. Knobloch, J.; Schmitz, I.; Götz, K.; Schulze-Osthoff, K.; Rüther, U. Thalidomide induces limb anomalies by PTEN stabilization, Akt suppression and Stimulation of Caspase-dependent cell death. Mol. Cell. Biol. 2008, 28, 529-538.
6. Parman, T.; Wiley, M. J.; Wells, P. G. Free radical-mediated oxidative DNA damage in the mechanism of thalidomide teratogenicity. Nat. Med 1999, 5, 582-585.
7. Buetler, T. M.; Krauskopf, A.; Ruegg, U. T. Role of superoxide as a signaling molecule. News Physiol. Sci. 2004, 19, 120-123.
8. Wells, P. G.; Bhuller, Y.; Chen, C. S.; Jeng, W.; Kasapinovic, S.; Kennedy, J. C.; Kim, P. M.; Laposa, R. R.; McCallum, G. P.; Nicol, C. J.; Parman, T.; Wiley, M. J.; Wong, A. W. Molecular and biochemical mechanisms in teratogenesis involving reactive oxygen species. Toxicol. Appl. Pharmacol. 2005, 207, 354-366.
9. Schnabel, D.; Salas-Vidal, E.; Narvaez, V.; Sanchez-Carbente Mdel, R.; Hernandez-Garcia, D.; Cuervo, R.; Covarrubias, L. Expression and regulation of antioxidant enzymes in the developing limb support a function of ROS in interdigital cell death. Dev. Biol. 2006, 291, 291-299.
10. Anderson, M. E. Determination of glutathione and glutathione disulfide in biological samples. Methods Enzymol. 1985, 113, 548-555.
11. Watson, R. W.; Rotstein, O. D.; Nathens, A. B.; Dackiw, A. P.; Marshall, J. C. Thiol-mediated redox regulation of neutrophil apoptosis. Surgery 1996, 120, 150-158.
12. 2. Biochem. Biophys. Res. Commun. 2001, 280, 1279-1285.
13. Grotewold, L.; Ruther, U. The Wnt antagonist Dkk1 is regulated by Bmp signaling and c-Jun and modulates programmed cell death. EMBO J. 2002, 21, 966-975.
14. Knobloch, J.; Ruther, U. Shedding light on an old mystery: Thalidomide suppresses survival pathways to induce limb defects. Cell Cycle 2008, 7, 1122-1128.
15. Hansen, J.; Harris, C. A novel hypothesis for thalidomide-induced limb tertogenesis: redox misregulation ofthe NF-kappaB pathway. Antioxid. Redox Signaling 2004, 6, 1-14.
16. Aerbajinai, W.; Zhu, J.; Gao, Z.; Chin, K.; Rodgers, G. P. Thalidomide induces gamma-globin gene expression through increased reactive oxygen species-mediated p38 MAPK signaling and histone H4 acetylation in adult erythropoiesis. Blood 2007, 110, 2864-71.
17. Andela, V. B.; Sheu, T. J.; Puzas, E. J.; Schwarz, E. M.; O'Keefe, R. J.; Rosier, R. N. Malignant reversion of a human osteosarcoma cell line, Saos-2, by inhibition of NFkappaB. Biochem. Biophys. Res. Commun. 2002, 297, 237-241.
18. San Martin, A.; Du, P.; Dikalova, A.; Lassegue, B.; Aleman, M.; Gongora, M. C.; Brown, K.; Joseph, G.; Harrison, D. G.; Taylor, W. R.; Jo, H.; Griendling, K. K. Reactive oxygen species-selective regulation of aortic inflammatory gene expression in Type 2 diabetes. Am. J. Physiol.: Heart Circ. Physiol 2007, 292, H2073-2082.